Virax Biolabs Group (Virax Biolabs Group) Debt-to-Asset : 0.03 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Debt-to-Asset?

Virax Biolabs Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.05 Mil. Virax Biolabs Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.13 Mil. Virax Biolabs Group's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $7.03 Mil. Virax Biolabs Group's debt to asset for the quarter that ended in Sep. 2023 was 0.03.

Virax Biolabs Group Debt-to-Asset Historical Data

The historical data trend for Virax Biolabs Group's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Debt-to-Asset Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Debt-to-Asset

0.02

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial			2.33	-	0.07	0.02	0.03

Competitive Comparison of Virax Biolabs Group's Debt-to-Asset

For the Biotechnology subindustry, Virax Biolabs Group's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Debt-to-Asset falls into.

Virax Biolabs Group Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Virax Biolabs Group's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.146	+	0)	/	9.812
	=	0.01

Virax Biolabs Group's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.05	+	0.132)	/	7.025
	=	0.03

Virax Biolabs Group (NAS:VRAX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Virax Biolabs Group Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.